• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

For Industry

  • Print
  • Share
  • E-mail

Public Meeting on Lung Cancer Patient-Focused Drug Development

On June 28, 2013, FDA conducted a public meeting on Patient-Focused Drug Development for lung cancer. FDA is interested in obtaining patient input on the impact of lung cancer on daily life and the available therapies for lung cancer.

Date: June 28, 2013 
Time: 8:30 a.m. to 12:30 p.m 
Location:

FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B and C (Great Room)
Silver Spring, MD 20993  

(Information about arrival to FDA's White Oak campus)

Registration: To register for this meeting, visit http://patientfocusedlungcancer.eventbrite.com.
Registration closed on June 21, 2013.  

To submit comments to the docket, go to http://www.regulations.gov/#!docketDetail;D=FDA-2013-N-0596.

The comment period has been extended. Electronic and written comments may be submitted to the docket by August 28, 2013.

Please note: In the July 5, 2013 Federal Register, the reference number for the original June 5, 2013 Federal Register is incorrect. Please refer to Federal Register (78 FR 33851): https://federalregister.gov/a/2013-13243

Webcast Recordings 
(archived) 


Summary Report